SEC Form 4 · accession 0000899243-18-017943
INFINITY PHARMACEUTICALS, INC. · INFI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffery Kutok
Officer — Chief Scientific Officer
Period of report
Jun 22, 2018
Accepted (ET)
Jun 25, 2018 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001113148
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 22, 2018 | S | 14,313 | $2.0048 | D | 14,313 | D | |
| Common Stock | holding | — | — | — | 8,012 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The disposition reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 29, 2018.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.00 to $2.025, inclusive. The reporting person undertakes to provide to Infinity Pharmaceuticals, Inc., any security holder of Infinity Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2.